Evaluation of Patient Reported Outcomes (PRO) After Total Knee Arthroplasty (TKA) Under Spinal Anesthesia
Evaluation of the Patient Reported Outcomes After Sensor-guided Total Knee Arthroplasty Under Spinal Anesthesia With Limited Motor-block.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- New York University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients will be screened for eligibility based on whether they have chronic knee pain as a result of an arthritis-related condition.
- Patient with chronic knee pain who is indicated for total hip or knee replacement surgery
- Patient is at least 50 years of age
- Patient is willing to participate in pre- and postoperative surveys
Exclusion Criteria:
- Failure to complete pre-operative surveys.
- Revision Total Knee Arthroplasty
- Prior ipsilateral knee surgery such as ligament reconstruction or osteotomy
- Contralateral Total Knee Arthroplasty
- Prior tibial plateau fracture
- Ligamentous Insufficiency
- History of fibromyalgia, chronic fatigue syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard of Care Spinal Surgery
Patients will be given spinal anesthesia with 2.6 mL of 0.5% isobaric bupivacaine.
|
TKA under standard of care spinal surgery.
|
|
Experimental: Sensor Guided Spinal Surgery
The Verasense Knee System device (OrthoSensor inc., Dania Beach, Florida) is a sterile sensor system that replaces the tibial insert trials used during surgery.
The sensor contains a microprocessor and integrated nanosensor system, which wirelessly transmits real-time data to a portable graphic display unit used for read-out of the data.
The sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces.
Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
|
Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces.
Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knee Society Score (KSS)
Time Frame: Month 12 Post-Surgery
|
The Knee Society Score (KSS) comprises two sections (each worth 100 points) for a maximum 200 points.
One section is the Knee Society Clinical Score (KSCS) - points are given for pain, motion, and stability and points are deducted for flexion contracture, extension lag, and misalignment.
The other section is the Knee Society Functional Score (KSFS) - points are assigned for walking distances and climbing stairs and points are deducted for use of walking aids.
For each section, a score of 80-100 = excellent, 70-79 = good; 60-69 = fair; and < 60 = poor.
|
Month 12 Post-Surgery
|
|
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: Month 12 Post-Surgery
|
The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee.
It is a 42-item questionnaire, including 5 subscales: symptoms, pain, function in daily living (ADLs), sports/recreation, and quality of life.
The maximum score a patient can achieve is 100, indicating no knee problems.
The minimum score is zero, indicating severe knee problems.
|
Month 12 Post-Surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Arthur Hertling, MD, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 16-00129
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.